Aim: Research shows that subclinical hypothyroidism (SCH) is related to an increased carotid intima–media thickness (CIMT), a surrogate marker of subclinical cardiovascular disease (CVD). It is controversial whether or not SCH should be treated to reduce CVD morbidity and mortality. This meta-analysis aimed to determine whether SCH is associated with an increase in CIMT as compared to Euthyroidism (EU) and whether thyroxin (T4) treatment in SCH can reverse the change in CIMT.

Methods: Two independent reviewers conducted an extensive database research up to December 2016. A total of 12 clinical trials discussed the effect of Thyroxin on CIMT values at pre- and post-treatment in subjects with SCH.

Results: CIMT was significantly higher among SCH (n = 280) as compared to EU controls (n = 263) at baseline; the pooled weighted mean difference (WMD) of CIMT was 0.44 mm [95% confidence interval (CI) 0.14, 0.74], p = 0.004; I² = 65%. After treatment with thyroxin in subjects with SCH (n = 314), there was a statistically significant decrease in CIMT from pre- to post-treatment; the pooled WMD of CIMT decrease was [WMD = 0.32; 95% CI (-0.47, -0.16), p = <0.0001; I² = 2%], and it was no longer different from EU controls [WMD 0.13 mm; 95% CI (-0.04, 0.30); p = 0.14; I² = 27%]. The total cholesterol (TC), triglycerides (TG), and low-density lipoprotein (LDL) were higher in SCH as compared to EU controls and decreased significantly after treatment with thyroxin.

Conclusion: This meta-analysis shows that thyroxin therapy in subjects with SCH significantly decreases CIMT and improves lipid profile, modifiable CVD risk factors. Thyroid hormone replacement in subjects with SCH may play a role in slowing down or preventing the progression of atherosclerosis.

Key words: Subclinical hypothyroidism, Euthyroid/Euthyroidism, Carotid intima–media thickness, Thyroxin treatment, Dyslipidemia, Clinical trials, Meta-analysis
ting of normal free thyroid hormone levels, both FT3 and FT4\(^1\)). In the recent past, the detection of SCH has been increasing with evolving diagnostic tests. The prevalence of SCH is greater than that of type 2 diabetes mellitus (estimated to be 5–10%) and with an increased occurrence among females and the elderly\(^2,3\)). The prevalence of SCH is almost up to 20% in females older than 60 years\(^2\).

SCH has also been considered to increase the risk of atherosclerosis alongside overt hypothyroidism\(^5,6\)). The association of overt hypothyroidism with atherosclerotic disease has been well established, and treating those patients with levothyroxine has shown proven benefits in reducing cardiovascular risk\(^7\)). There is evidence that SCH had effects on some important cardiovascular risk factors, such as high blood pressure, dyslipidemia, and altered coagulability\(^8,9\)). However, how significant a role does SCH play as an independent risk factor for atherosclerosis was debatable, until a recent population-based study proved otherwise\(^10,11\)).

Carotid Intima–media thickness (CIMT), measured using carotid ultrasonography, is trusted to be a good marker of atherosclerotic changes in early stages apart from being accepted as a surrogate endpoint for cardiovascular events\(^12,13\)). Many studies have shown that SCH is independently related to a significant increase in CIMT in relatively healthy subjects when compared with euthyroid (EU) healthy matched groups\(^14-19\)). Several studies, including some randomized controlled trials, have shown reduced cardiovascular risk, including a significant reduction in CIMT in subjects with SCH treated with levothyroxin\(^15,17,18,20-28\)).

The primary focus of this review and meta-analysis is to determine the differences of CIMT between subjects with SCH and EU controls at baseline as well as to demonstrate the effects of thyroxine treatment on CIMT reduction from pre-to-post treatment after a follow-up period. We hypothesized that “thyroxin treatment in subjects with SCH causes a decrease in CIMT values from pre-to-post treatment.”

**Methods**

We conducted this systematic review and meta-analysis using the PRISMA statement as guideline\(^29\)).

**Inclusion Criteria**

In this systematic review and meta-analysis, we included the clinical trials that reported the treatment of subjects with SCH and discussed the effects of thyroxin treatment on CIMT reduction in subjects with SCH from pre- to post-treatment during a follow-up period. Our hypothesis was to analyze “the effects of thyroxin treatment on CIMT reduction in patients with SCH during a follow-up period.” We selected original published clinical trials with no language and regional limitations. According to the hypothesis, we defined a strict inclusion and exclusion criteria as described below.

**Inclusion Criteria were as follows**

1. Studies investigating subjects with SCH (the mean pretreatment basal serum TSH concentration must have been above the upper limit of normal for the assay used in the study, but less than 20 mIU/L along with a normal T4 level) and comparing them with subjects with EU; (2) Use of the ultrasound method to measure CIMT both in subjects with SCH and EU at baseline; and (3) Use of the ultrasound method to measure CIMT in subjects with SCH at pre- and post-treatment with thyroxin along a follow-up period. We included studies that discussed demographically, anthropometrically, and metabolically matched SCH and EU control groups to discuss the effect of SCH on CIMT and the role of thyroxin treatment on CIMT reduction in subjects with SCH.

We excluded all studies that discussed subjects with chronic diseases/risk factors that can potentially affect CIMT and thyroid function tests. Exclusion criteria were as follows: (1) Use of overt clinical hypothyroidism/hyperthyroidism subjects; (2) Use of subjects on any medications to treat hypo and hyper functions of thyroid, including thyroid cancer; (3) Use of any subjects with established coronary artery disease (CAD), congestive heart failure (CHF), obesity (BMI ≥30 kg/m\(^2\)), chronic liver disease, chronic kidney failure, chronic inflammatory diseases, hypophyseal insufficiency, or any type of cancer; (4) Use of any pregnant, lactating, or menopausal women; (6) Use of any subject using medications that can potentially alter thyroid function tests (e.g., amiodarone, carbamazepine, carbipora, phenytoin, furosemide, haloperidol, heparin, interferon, levodopa, Lithium, metoclopramide, propranolol, primidone, rifampicin, and valproic acid.) (7) Use of any subject using medications that can potentially affect hormonal changes in the body (e.g., antidiabetics, glucocorticoid therapy, OCP, steroids, GnRH agonists and antagonists, insulin-sensitizing drugs, antiandrogens, and aspirin), as well as affect blood pressure (anti-hypertensives) or lipid levels (anti-hyperlipidemics); and (8) Use of different therapeutic approaches apart from thyroxin/T4 treatment of subjects with SCH.

**Information Sources and Search Strategy**

An extensive literature search, not limited by language and regions, was performed, which was directed
reference sections of the finally selected studies were screened for additional eligible studies. In rare cases, authors of the relevant studies were contacted when more information or clarification was needed. **Fig. 1** shows the PRISMA flow diagram of the effect of thyroxin treatment on the reduction of CIMT values in subjects with SCH at pre- to post-treatment.

**Study Selection**

A total of 12 original studies included in the final review had a sample size ranging from 20 to 5615. The total sample of subjects...
with SCH was \((n = 380)\) and that with EU controls was \((n = 367)\). First, we screened 38 studies that discussed CIMT values in subjects with SCH and EU at baseline. Of these 38 studies, only 12 studies were clinical trials that discussed the treatment of SCH with thyroxin and measured CIMT values at pre- and post-treatment with a follow-up period. We excluded all other studies \((n = 26)\) as these were case control, and/or cross-sectional, case reports/editorials, and none of these studies discussed the treatment of subjects with SCH. Among these finally selected 12 studies for review, 11 studies were included in the meta-analysis as the study by Köroglu et al. 2012\(^{24}\) did not report any mean CIMT values at pre- and post-treatment with thyroxin.

### Data Extraction and Quality Assessment

Three authors (Machavarapu, A; Saxena, A; Nguyen, M) extracted the data on an excel sheet independently from eligible studies related to subjects with SCH, EU controls, as well as the treatment of subjects with SCH. The data extracted included first author last name, publication year, study design, country of origin, study subjects’ age, sample size, gender, cut-off TSH value to diagnose SCH, systolic blood pressure (SBP), diastolic blood pressure (DBP), lipid levels [total cholesterol (TC), triglycerides (TG) high-density lipoprotein (HDL), low-density lipoprotein (LDL), TSH], and CIMT in subjects with EU and SCH at baseline as well as at pre- and post-treatment with thyroxin. In different studies selected for a review, different biochemical and hormones assays were used to measure all classes of lipids and TSH levels. All studies used Doppler ultrasound of carotid arteries to measure CIMT. CIMT was assessed as the distance between the lumen–intima interface and the media–adventitia interface. Any type of disagreement in data collection was resolved by discussion with a fourth reviewer (Kandimalla, Y). In all clinical trials included in this meta-analysis, the confounding factors that may affect CIMT, for example, use of recent previous/present thyroid medications or other medications that affect thyroid hormones, any thyroid disease other than SCH, smoking, HTN, DM, CVD, stroke, chronic liver disease, and chronic kidney disease were balanced between subjects with SCH and EU controls by the respective authors of each included study. All studies in this review have clearly mentioned about the research approval of the institutional ethical committee and participants in the studies completed and signed the informed consent form.

### Data Synthesis and Analysis

The baseline mean CIMT as well as the standard deviations of CIMT were extracted in subjects with SCH and EU controls. The mean CIMT values and standard deviations were also extracted in subjects with SCH at pre- and post-treatment with thyroxin. We used RevMan 5 free version to conduct the data analysis\(^{31}\). The overall variation among studies termed as heterogeneity was calculated by \(I^2 (\tau^2)\) statistics. The square root of this number is the estimated standard deviation of the underlying effects across studies. The estimate of the between-study variance can be measured via a fixed- or random-effect model. We calculated the weighted mean difference (WMD) or the standardized mean difference (SMD) with a 95% confidence interval (CI) to calculate the pooled effect size using a fixed- or random-effect model as appropriate. Under a fixed-effect model, we assume that there is one true effect size that is shared by all the included studies. It follows that the combined effect is our esti-
imate of this common effect size. In contrast, under a random-effect model, we allow that the true effect could vary from study to study and we try to estimate the mean of a distribution of true effects. Large studies may produce more precise estimates of a true effect than small studies, but each study estimates a different effect size. Therefore, the weights assigned under a random-effect model are more balanced as compared with that in a fixed-effect model. WMD with a 95% CI of CIMT values was measured for subjects with SCH and EU at baseline. WMD with a 95% CI of CIMT was also measured for subjects with SCH at pre- and post-treatment periods with thyroxin. Statistical heterogeneity was tested using Tau² with \( p < 0.05 \) considered as significant.

Two authors (Khan, IM; Aziz, M) used the Cochrane risk of bias tool to determine the risk of a bias graph (Fig. 2) and that of a bias summary (Fig. 3) in individual studies per methodological quality of included clinical trials. The Cochrane risk of bias tool is based on the following items: Random sequence generation, allocation concealment, blinding of participant and personnel, outcome data blinding, incomplete outcome data, selective reporting, and other bias. A subgroup/sensitivity analysis was used to explore the potential sources of between-studies heterogeneity according to the type of studies, study quality by the JADAD score as a low (\( \leq 2 \) score) or high (\( \geq 3 \) score) range of quality score, BMI \( \leq 25 \) kg/m², TSH values as \( \leq 10 \) mIU/l and \( > 10 \) mIU/l, and duration of treatment as less than 6 months and more than 6 months. Potential publication bias was assessed and represented graphically with funnel plots of WMD or SMD versus standard error. The decision to use the results of the Cochrane risk of bias assessment tool and publication bias among studies was taken by discussing with senior authors (Nasir, K; Kandimalla, Y; Veledar, E).

Results

Study Characteristics

Table 1 shows the characteristics of subjects with SCH and EU controls. All 12 studies discussed the comparison of CIMT values in subjects with SCH and EU at baseline as well as the effect of thyroxin treatment on CIMT reduction in subjects with SCH. However, only 9 out of 12 studies reported the mean CIMT values of subjects with SCH and EU controls at baseline and 11 out of 12 studies reported the effect of thyroxin treatment on CIMT reduction from pre- to post-treatment. Table 2 shows the JADAD score for the quality of each study, duration of follow-up, TSH and CIMT values at pre- and post-treatment, and change and percentage change in TSH and CIMT values from pre- to post-treatment.

CIMT Values Among Subjects with SCH and EU at Baseline

The 9 clinical trials reported differences of CIMT values among subjects with SCH and EU controls at baseline (SCH, \( n = 280 \); EU, \( n = 263 \)). There was a statistically significant heterogeneity among studies (\( I^2 = 65\% ; p = 0.004 \)). A random-effect model was used to calculate the pooled WMD and the overall WMD showed significantly higher CIMT values among subjects with SCH as compared to those with EU [WMD 0.44 mm; 95% CI (0.14, 0.74); \( p = 0.004 \)] (Fig. 4a).
Table 1. Characteristics of study population

<table>
<thead>
<tr>
<th>Author(s), Year Published &amp; Study Type</th>
<th>Country</th>
<th>Sample (SCH/EU)</th>
<th>Age (yr)</th>
<th>TSH cutoff value (mIU/l)</th>
<th>TSH at baseline (SCH/EU)</th>
<th>CIMT (mm) at baseline: SCH/EU</th>
<th>Exclusion criteria used</th>
<th>SCH and EU Groups matched for</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monzani et al. 2004 18; Clinical trial</td>
<td>Italy</td>
<td>45/32</td>
<td>37 ± 11/ 30 ± 10</td>
<td>&gt; 3.6</td>
<td>6.03 ± 8.4/ 1.19 ± 1.6</td>
<td>0.76 ± 0.14/ 0.63 ± 0.07</td>
<td>Thyroid Rx., subjects &gt; 55 yr, obese (BMI &gt; 30 kg/m²), smoking, HTN, DM, CVD, CRF, CLD.</td>
<td>sex, age, BMI</td>
</tr>
<tr>
<td>Duman et al. 2007 19; Clinical trial</td>
<td>Turkey</td>
<td>20/20</td>
<td>37.0 ± 12.6/ 37.0 ± 12.6</td>
<td>&gt; 4.2</td>
<td>10.9 ± 5.8/ 2.3 ± 0.8</td>
<td>0.65 ± 0.99/ 0.54 ± 0.10</td>
<td>Taking any medication, Obesity (BMI &gt; 30 kg/m²), DM, HTN, CHD, CLD, CRF, FH, PVD, age &lt; 18 yrs or &gt; 60 yrs, smoking, menopause, pregnancy.</td>
<td>sex, age.</td>
</tr>
<tr>
<td>Adrees et al. 2009 20; Clinical trial</td>
<td>Ireland</td>
<td>56/56</td>
<td>50 ± 9/ NR</td>
<td>13.2 ± 4.5/ 1.9 ± 1.0</td>
<td>0.82 ± 0.2/ NR</td>
<td>Hx. of IHD, TIA, HTN, DM, or impaired fasting glycaemia, smoking, coelidic disease, pernicious anemia.</td>
<td>age, BMI.</td>
<td></td>
</tr>
<tr>
<td>Kim et al. 2009 21; Clinical trial</td>
<td>Korea</td>
<td>36/32</td>
<td>36.0 ± 6.2/ 36.1 ± 5.4</td>
<td>&gt; 5.5</td>
<td>11.48 ± 4.7/ 1.60 ± 0.60</td>
<td>0.67 ± 0.11/ 0.57 ± 0.08</td>
<td>Hx. of thyroid disease or Rx., thyroidectomy, or radioiodine therapy, DM, HTN, serum Creatinine &gt; 1.3 mg/dl, smoking, statin use, previous pregnancy in the last 1 yr, postmenopausal state.</td>
<td>gender, age, BMI</td>
</tr>
<tr>
<td>Kebapcilar et al. 2010 22; Clinical trial</td>
<td>Turkey</td>
<td>38/19</td>
<td>49.47 ± 10.0/ 49.95 ± 8.12</td>
<td>&gt; 5.0</td>
<td>11.26 ± 7.5/ 1.48 ± 1.12</td>
<td>0.64 ± 0.13/ 0.57 ± 0.08</td>
<td>DM, CHD, CLD, CRF, other systemic diseases, morbid obesity, FH, cancer. MEDS: anti-hyperlipidemics, antihypertensives, acetylsalicylic acid, anti-thrombocytes, HRT, multivitamins, or excessive alcohol.</td>
<td>age, smoking habit, waist circumference, BMI</td>
</tr>
<tr>
<td>Cabral et al. 2011 23; Clinical trial</td>
<td>Brazil</td>
<td>32/NR</td>
<td>47.59 ± 8.4/ 43.36 ± 9.8</td>
<td>&gt; 4.0</td>
<td>6.79 ± 2.0/ 6.77 ± 1.9</td>
<td>0.66 ± 0.11/ NR</td>
<td>Hx. of previous thyroid disease, THS &gt; 12 mIU/ml, obesity, HTN, DM, CAD, CLD, CRF, alcohol use. MEDS*: amiodarone, corticosteroids, estrogen, lithium, anti-lipids, diuretics, anti-diabetes, antihypertensive, and drugs to treat obesity.</td>
<td>NR</td>
</tr>
<tr>
<td>Koroglu et al. 2012 24; Clinical trial</td>
<td>Turkey</td>
<td>30/NR</td>
<td>44.0 ± 11.6/ 47.9 ± 14.6</td>
<td>NR</td>
<td>7.5 ± 1.5/ 6.8 ± 1.4</td>
<td>NR/NR</td>
<td>CAD, CLD, CRF, chronic inflammatory disease, hypophysal insufficiency, Thyroid Rx. in recent 3 months, use of statins, use of HRT.</td>
<td>NR</td>
</tr>
<tr>
<td>Akkolca et al. 2014 25; Clinical trial</td>
<td>Turkey</td>
<td>20/20</td>
<td>34.47 ± 1.4/ 35.25 ± 2.21</td>
<td>NR</td>
<td>8.97 ± 1.1/ 3.50 ± 0.43</td>
<td>0.74 ± 0.63/ 0.39 ± 0.72</td>
<td>Hx. of thyroid Rx. , HTN, DM, CAD, CLD, CRF, cancer, FH, use of lipid lowering drugs, BMI &lt; 20 kg/m² or &gt; 30 kg/m², smoking.</td>
<td>Age, height, weight, BMI</td>
</tr>
<tr>
<td>Ural et al. 2014 26; Clinical trial</td>
<td>Turkey</td>
<td>56/46</td>
<td>41.32 ± 14.4/ 36.07 ± 10.58</td>
<td>&gt; 4.2</td>
<td>6.77 ± 2.9/ 1.65 ± 0.913</td>
<td>0.533 ± 0.112/ 0.5 ± 0.086</td>
<td>Hx. of thyroid disease or Rx, thyroidectomy, obesity, DM, HTN, CVD, CLD, CRF, radioiodine therapy, statin use, alcohol use.</td>
<td>NR</td>
</tr>
<tr>
<td>Yataci et al. 2014 27; Clinical trial</td>
<td>Turkey</td>
<td>43/30</td>
<td>35.2 ± 10.7/ 34.5 ± 8.2</td>
<td>&gt; 4</td>
<td>6.0 ± 1.4/ 2.0 ± 0.3</td>
<td>0.51 ± 0.09/ 0.48 ± 0.04</td>
<td>DM, HTN, heart failure, IHD, valvular disease, CAD, CLD, CRF, rheumatological disease, malignancy. MEDS: antihypertensives, antihyperlipidemias, acetylsalicylic acid, HRT.</td>
<td>Sex, age, SBP, DBP, BMI</td>
</tr>
<tr>
<td>Cerbone et al. 2016 28; Clinical trial</td>
<td>Italy</td>
<td>39/39</td>
<td>9.18 ± 3.56/ 9.45 ± 3.62</td>
<td>&gt; 4.5</td>
<td>6.30 ± 1.0/ 2.92 ± 0.68</td>
<td>0.44 ± 0.08/ 0.44 ± 0.06</td>
<td>Chronic diseases, chromosomal and genetic syndromes, previous or current thyroid diseases, use of drugs that may interfere with thyroid function, previous irradiation in the neck region, detection of SCH at neonatal screening, familiar history of genetic lipid disorders or early CVD.</td>
<td>age, height, BMI, SBP, DBP</td>
</tr>
<tr>
<td>Niknam et al. 2015 29; Clinical trial</td>
<td>Iran</td>
<td>25/25</td>
<td>35.9 ± 7.6/ 37.5 ± 7.3</td>
<td>&gt; 4.5</td>
<td>7.19 ± 1.2/ 2.4 ± 0.55</td>
<td>0.56 ± 0.09/ 0.58 ± 0.08</td>
<td>Rx. of hypothyroidism, CVD, CRF, CLD, malignancies, or CVA, HTN, DM, obesity (BMI &gt; 30 kg/m²), smoking, pregnancy, lactating women.</td>
<td>sex, age.</td>
</tr>
</tbody>
</table>

SCH = Subclinical Hypothyroidism, NR = Not reported, Hx = History of, Rx = Treatment of, HTN = Hypertension, DM = Diabetes Mellitus, ATH = Atherosclerotic disease (e.g. CAD, PAD etc.), CAD = Coronary Artery Disease, IHD = Ischemic Heart Disease, CHD = Coronary Heart Disease, CHF = Congestive Heart Failure, CLD = Chronic Liver Disease, CRF = Chronic Renal Failure, CARS = Coronary Artery Revascularization Surgery, TC = Total cholesterol, HCL = Hypercholesterolemia, CAH = Congenital adrenal hyperplasia, HPRL = hyperprolactinemia, WC = Waist Circumference, FH = Familial Hypercholesterolemia, CD = Cushing’s disease, TIA = Transient Ischemic Attacks, HRT = Hormone Replacement Therapy, MNG = Multinodular Goiter, DBP = Diastolic Blood Pressure, SBP = Systolic Blood pressure. MEDS* use of any drugs that alter Thyroid function test.
A subgroup analysis was also conducted by considering TSH cut-off values as ≤10 mIU/l and >10 mIU/l in subjects with SCH and comparing their CIMT values with those of EU controls at baseline. Subjects with SCH with TSH ≤10.0 mIU/l exhibited a near significant increase in CIMT as compared to EU controls at baseline; WMD was 0.36 mm with 95% CI (−0.01, 0.73); p=0.06 with significant heterogeneity; I²=68%; p=0.009. However, WMD between subjects with SCH with a mean TSH >10.0 mIU/l and EU controls was 0.61 with 95% CI (0.13, 1.10); p<0.01, and heterogeneity was decreased to I²=56%; p=0.10. This shows that with a decreased between-studies heterogeneity, subjects with SCH with TSH >10.0 mIU/l exhibited a significantly higher WMD increase in CIMT as compared to SCH with TSH ≤10.0 mIU/l when compared to EU controls (WMD 0.61 vs. 0.36). We also conducted a subgroup analysis based on BMI groups. We calculated WMD with 95% CI by excluding all the studies with BMI >25 kg/m² (as an increase in BMI is related to an increase in CIMT). We used only those studies that reported a mean BMI of subjects with SCH and EU as <25 kg/m². CIMT was still significantly higher in subjects with SCH as compared to EU [WMD 0.51; 95% CI (0.14, 0.89); p=0.008] with significant heterogeneity, I²=70%; p=0.005. As increasing age, smoking, hypertension, diabetes, non-alcoholic fatty liver disease, dyslipidemia, polycystic ovarian disease, and menopause are related to increased CIMT and increased CVD risks, we removed all studies that discussed subjects with SCH and EU controls with one or multiple of these risk factors. The remaining 8 studies still showed a significant increase in CIMT among subjects with

<table>
<thead>
<tr>
<th>Authors</th>
<th>N (SCH): Pre-Rx/Post-Rx; % Females</th>
<th>JADAD Score</th>
<th>Primary disease</th>
<th>Rx. given</th>
<th>Dose of Thyroxin (µg/day)</th>
<th>Duration of Rx. (Mo)</th>
<th>TSH (mIU/L) in SCH (Pre-Rx)</th>
<th>TSH (mIU/L) in SCH (Post-Rx)</th>
<th>Change % change</th>
<th>CIMT (mm) in SCH (Pre-Rx)</th>
<th>CIMT (mm) in SCH (Post-Rx)</th>
<th>Change % change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monzani et al. 2004 (4)</td>
<td>23/23; 82%</td>
<td>4</td>
<td>SCH</td>
<td>T4</td>
<td>25</td>
<td>6</td>
<td>6.03±8.4</td>
<td>1.32±1.7</td>
<td>−4.71</td>
<td>0.76±0.14</td>
<td>0.67±0.13</td>
<td>−0.09</td>
</tr>
<tr>
<td>Duman et al. 2007 (5)</td>
<td>20/20; 100%</td>
<td>4</td>
<td>SCH</td>
<td>T4</td>
<td>25</td>
<td>8</td>
<td>10.9±5.8</td>
<td>2.0±1.1</td>
<td>−8.9</td>
<td>0.65±0.99</td>
<td>0.55±0.08</td>
<td>−0.1</td>
</tr>
<tr>
<td>Adrees et al. 2009 (6)</td>
<td>56/52; 100%</td>
<td>1</td>
<td>SCH</td>
<td>T4</td>
<td>50</td>
<td>18</td>
<td>13.2±4.5</td>
<td>1.6±1.8</td>
<td>−11.6</td>
<td>0.82±0.2</td>
<td>0.71±0.2</td>
<td>−0.11</td>
</tr>
<tr>
<td>Kim et al. 2009 (7)</td>
<td>36/28; 86.1%</td>
<td>3</td>
<td>SCH</td>
<td>T4</td>
<td>67</td>
<td>18</td>
<td>11.48±4.70</td>
<td>1.26±3.30</td>
<td>−10.22</td>
<td>0.67±0.11</td>
<td>0.60±0.10</td>
<td>−0.07</td>
</tr>
<tr>
<td>Kębapcilar et al. 2010 (8)</td>
<td>38/38; 82%</td>
<td>3</td>
<td>SCH</td>
<td>T4</td>
<td>25;50</td>
<td>6</td>
<td>11.26±7.54</td>
<td>2.29±1.43</td>
<td>−8.97</td>
<td>0.64±0.13</td>
<td>0.63±0.12</td>
<td>−0.01</td>
</tr>
<tr>
<td>Cabral et al. 2011 (9)</td>
<td>14/14; 100%</td>
<td>4</td>
<td>SCH</td>
<td>T4</td>
<td>44.23</td>
<td>12</td>
<td>6.79±2.0</td>
<td>3.02±0.89</td>
<td>−3.77</td>
<td>0.66±0.11</td>
<td>0.66±0.15</td>
<td>0</td>
</tr>
<tr>
<td>Koroğlu et al. 2012 (10)</td>
<td>30/30; 97%</td>
<td>4</td>
<td>SCH</td>
<td>T4</td>
<td>50</td>
<td>6</td>
<td>7.5±1.5</td>
<td>3.6±0.6</td>
<td>−3.9</td>
<td>0.74±0.63</td>
<td>0.43±0.32</td>
<td>−0.31</td>
</tr>
<tr>
<td>Akloca et al. 2014 (11)</td>
<td>20/20; 75%</td>
<td>3</td>
<td>SCH</td>
<td>T4</td>
<td>NR</td>
<td>7</td>
<td>8.97±1.1</td>
<td>2.94±0.43</td>
<td>−6.03</td>
<td>0.74±0.63</td>
<td>0.43±0.32</td>
<td>−0.31</td>
</tr>
<tr>
<td>Unsal et al. 2014 (12)</td>
<td>56/56; 91%</td>
<td>1</td>
<td>SCH</td>
<td>T4</td>
<td>25;50</td>
<td>6</td>
<td>6.77±2.90</td>
<td>2.73±1.17</td>
<td>−4.04</td>
<td>0.53±0.11</td>
<td>0.51±0.13</td>
<td>−0.02</td>
</tr>
<tr>
<td>Yavuz et al. 2014 (13)</td>
<td>23/23; 98%</td>
<td>4</td>
<td>SCH</td>
<td>T4</td>
<td>NR</td>
<td>6</td>
<td>5.9±1.2</td>
<td>1.7±0.9</td>
<td>−4.2</td>
<td>0.51±0.09</td>
<td>0.46±0.07</td>
<td>−0.05</td>
</tr>
<tr>
<td>Cerbone et al. 2016 (14)</td>
<td>39/39; 51%</td>
<td>2</td>
<td>SCH</td>
<td>T4</td>
<td>50</td>
<td>24</td>
<td>6.30±1.01</td>
<td>2.82±1.31</td>
<td>−3.48</td>
<td>0.44±0.08</td>
<td>0.46±0.07</td>
<td>0.02</td>
</tr>
<tr>
<td>Niknam et al. 2016 (15)</td>
<td>25/25; 60%</td>
<td>1</td>
<td>SCH</td>
<td>T4</td>
<td>50</td>
<td>2</td>
<td>7.19±1.29</td>
<td>2.56±0.69</td>
<td>−4.63</td>
<td>0.56±0.09</td>
<td>0.57±0.08</td>
<td>0.01</td>
</tr>
</tbody>
</table>

*The JADAD score/scale or the Oxford quality scoring system, is a procedure to independently assess the methodological quality of a clinical trial. SCH=Subclinical Hypothyroidism, TSH=Thyroid stimulating hormone.*
SCH as compared to EU controls [WMD 0.42; 95% CI (0.09, 0.75); p = 0.01] with significant heterogeneity, I² = 68%; p = 0.002. The test for the overall effect of CIMT differences in a subgroup analysis was significant with Z = 4.88; p < 0.00001; with heterogeneity I² = 64%; p < 0.0001, and the test for subgroup differences was [Chi² = 0.80, df = 3 (p = 0.85), I² = 0%]. (Fig. 4b)

Effect of Thyroxin Treatment on CIMT Values in Subjects with SCH

All 12 studies discussed the effects of thyroxin treatment on CIMT reduction from pre- to post-treatment in subjects with SCH (n = 314) with the duration of treatment ranging from 2 to 24 months; however, 11 studies were included in the meta-analysis as one study by Koroglu et al. 2012 did not report the mean CIMT values in subjects with SCH at pre- and post-treatment with thyroxin. After treatment with thyroxin in subjects with SCH, there was a statistically significant decrease in CIMT from pre- to post-treatment. In a fixed-effect model, the pooled WMD of CIMT decrease in subjects with SCH from pre- to post-treatment with thyroxin was −0.32 mm with 95% CI (−0.47, −0.16), p < 0.0001 with heterogeneity, I² = 29%; p = 0.42. CIMT of SCH treated subjects was no longer different from matched EU subjects with WMD of 0.13 mm and 95% CI (−0.04, 0.30); p = 0.14 and heterogeneity, I² = 27%; p = 0.20 (Data not shown). (Figs. 5a & 5b)

A subgroup analysis was also conducted by considering prior thyroxin treatment TSH cut-off values as ≤10 mIU/l and >10 mIU/l in subjects with SCH and calculating the mean decrease in CIMT with thyroxin treatment from pre- to post-treatment periods. WMD of a decrease in CIMT from pre- to post-treatment in subjects with SCH with a prior treatment TSH ≤ 10 mIU/l was [WMD −0.30 mm; 95% CI (−0.50, −0.10); p = 0.003); with heterogeneity, I² = 5%; p = 0.39] and in subjects with SCH with a prior treatment TSH ≥ 10 mIU/l was [WMD −0.35 mm; 95% CI (−0.61, −0.08); p = 0.010; with heterogeneity, I² = 21%; p = 0.28]. Although WMD of a decrease in CIMT with thyroxin treatment was higher in subjects with SCH with a prior treatment TSH > 10 mIU/l as compared to those with TSH ≤ 10 mIU/l (WMD −0.35 vs. −0.30), this subgroup analysis indicates that thyroxin treatment is effective in both groups of subjects with SCH as compared to those with TSH ≤ 10 mIU/l. As compared to those with TSH > 10 mIU/l, there was a statistically significant increase in CIMT with thyroxin treatment was significant with Z = 3.04; 95% CI (−0.16, −0.00); p = 0.002 with heterogeneity, I² = 2%. We also conducted a subgroup analysis based on the JADAD score. We excluded all low-quality studies with the JADAD score ≤ 2. In all studies with the JADAD score ≥ 3, WMD of a decrease in CIMT from pre- to post-treatment in subjects with SCH was [WMD −0.40 mm; 95% CI (−0.61, −0.19); p = 0.0002]; with heterogeneity, I² = 8%; p = 0.37]. In a subgroup analysis, the test for the overall effect of CIMT reduction with thyroxin treatment was not significant with Z = 4.88; 95% CI (−0.61, −0.19); p = 0.0002; with heterogeneity, I² = 2%; p = 0.42. (Data not shown). (Fig. 5a)

Changes of Metabolic Parameters

Table 3 shows the differences in metabolic parameters between subjects with SCH and EU controls at baseline as well as after thyroxin treatment in subjects with SCH. As compared to EU controls, subjects with
SCH had a significant increase in the levels of TC [WMD, 0.71 mg/dl, 95% CI (0.23, 1.19); \( p = 0.004 \)], TG [WMD, 0.51 mg/dl, 95% CI (0.13, 0.90); \( p = 0.009 \)], LDL [WMD, 0.63 mg/dl, 95% CI (0.30, 0.95); \( p = 0.0001 \)], SBP [WMD, 6.16 mmHg, 95% CI (1.88, 10.45); \( p = 0.005 \)], and DBP [WMD, 0.43 mmHg, 95% CI (0.11, 0.76); \( p = 0.009 \)]. There was no significant difference in the HDL level in subjects with SCH and EU at baseline [WMD, 0.02 mg/dl, 95% CI (−0.24, 0.27); \( p = 0.90 \)]. We also discussed the changes in metabolic parameters in subjects with SCH at pre- to post-treatment with thyroxin along a treatment follow-up period. As compared to pre-treatment with thyroxin, the levels of TC (WMD, −0.53 mg/dl, 95% CI (−0.97, −0.09); \( p = 0.02 \)), TG (WMD, −0.55 mg/dl, 95% CI (−0.96, −0.13); \( p = 0.01 \)), LDL (WMD, −0.57 mg/dl, 95% CI (−0.98, −0.15); \( p = 0.007 \)), SBP (WMD, −0.33 mmHg, 95% CI (−0.62, −0.05); \( p = 0.02 \)), and DBP [WMD, −0.38 mmHg, 95% CI (−0.68, −0.08); \( p = 0.01 \)] were significantly decreased.
at post-treatment with thyroidin. Thyroidin treatment did not have any significant effect in increasing the HDL levels as there was no significant change in HDL (WMD, 0.03 mg/dl, 95% CI: −0.16, 0.22; \( p = 0.75 \)) in subjects with SCH from pre- to post-treatment with thyroidin.

Assessment of Publication Bias

We included at least 3 studies from a total of 12 studies that were eligible for this meta-analysis, which discussed the comparison of CIMT values. To assess any publication bias, we generated funnel plots of effect estimates against their standard errors (on a reversed scale) using free version of Review Manager software 5 (RevMan) (Figs. 6 and 7). We assessed the potential risk of publication bias through visual analysis of funnel plots. The studies reporting CIMT values in subjects with SCH and EU controls at baseline (\( n = 9 \)) generated a roughly symmetrical funnel plot indicating a positive standardized mean difference, while 2 studies were published with significantly higher values for a standardized mean difference and 1 study with a lower standardized mean difference. There is little possibility of publication bias toward reporting lower CIMT among EU controls. Studies reporting CIMT from pre- to post-treatment with thyroidin in subjects with SCH produced a symmetrical funnel plot with a relatively low SE hinting at a low risk of publication bias (Higgins 2011). One should be mindful that interpreting a funnel plot is subjective and an asymmetric funnel plot could be generated due to variability in selected sources, and it is not necessary that an actual publication bias can lead to an asymmetric funnel plot. We attempted to avoid bias in study selection by defining our search criteria a priori. These are discussed in detail under sensitivity analysis as well as in limitations and strengths of the study. We also addressed location bias by searching multiple databases, which included studies that were conducted in different countries or research settings in heterogeneous populations.

Medication doses provided to subjects with SCH were not similar across the studies. To account for this variability, we conducted a meta-regression analysis and accounted for different dose-related information. Results showed that there was an inverse relationship between increasing medication dosage and low CIMT, but the association was not significant. For each unit increase in dose, CIMT decreased by 0.004 units (\( \beta = -0.004; 95\% \text{ CI: } -0.03, 0.02; p = 0.70 \)). This could be due to the limited number of studies (\( n = 9 \)) included in the model.

Discussion

We conducted a meta-analysis to demonstrate the differences of CIMT values between subjects with SCH and EU controls at baseline. We also provided evidence of the effect of thyroidin treatment on CIMT reduction in subjects with SCH from pre- to post-treatment. The main results of this meta-analysis were as follows: (1) CIMT was significantly higher in subjects with SCH as compared to matched EU controls at baseline. (2) Thyroidin treatment in subjects with SCH was related to a significant reduction in CIMT from pre- to post-treatment over a follow-up period and CIMT values in post-treated subjects with SCH were no longer different from CIMT values of matched EU controls. (3) More than 6 months of thyroidin treatment showed a higher reduction in CIMT values as compared to less than 6 months of thyroidin treatment. (4) As compared to EU controls, SCH was also associated with a significant increase in TC, TG, LDL, SBP, and DBP. (4) Thyroidin treatment in subjects with SCH was related to a significant reduction in TC, TG, LDL, SBP, and DBP from pre- to post-treatment over a follow-up period. (5) Neither SCH was associated with a low level of HDL nor the treat-
ment of SCH caused a significant increase in the HDL level.

There is an increasing body of literature associating SCH with possible subclinical as well as clinical CVD outcomes. The subclinical CVD outcome can be presented as increased inflammatory markers, risk of hypertension, lipid disorders, increased CIMT, endothelial dysfunction, and arterial stiffness. Furthermore, some studies emphasized a positive association between SCH and clinical CVD outcomes, such as heart failure progression with less evidence in the oldest old population. Rodondi et al. showed in a meta-analysis that SCH was associated with an increased risk of CHD. In another meta-analysis of 11 prospective cohort studies, Rodondi et al. showed that SCH was associated with an increased risk of coronary heart disease (CHD) events and mortality. Such risk was greater among those with higher TSH levels, predominantly among those with a TSH level ≥ 10 mIU/L. Accord-
ing to some studies, SCH is not only related to worse CVD outcomes but also associated with pregnancy outcomes, infertility, other neuropsychiatric issues, and even cancer mortality. However, few studies failed to demonstrate such an association between SCH and CVD outcomes. Capola et al. showed a strong association between SCH and atrial fibrillation but did not support the association between SCH with other CVD-related morbidity and mortality. The main reason for the lack of evidence could be the use of a small sample size. The main mechanism of development of CVD in SCH could be related to low-grade chronic inflammation, abnormal lipid profile, insulin resistance, oxidative stress, arterial stiffness, and endothelial dysfunction. Moreover, these risk factors are accelerated in case of progression of SCH to overt thyroid disorders because there is a minimum of 2 to 5% per year to a maximum of 5 to 8% per year risk of progression of SCH to overt hypothyroidism depending on the degree of serum TSH elevation.

There is also an increasing controversy on whether or not subjects with SCH should be treated. Most research workers agree with treating SCH with persistent serum TSH ≥10.0 mIU/L and following an individualized therapy for those with TSH <10.0 mIU/L. This is because the risk of CVD increases as the TSH level increases beyond 10 mIU/L. The 2013 ETA Guidelines recommended thyroxin treatment of young patients with SCH (<70 years) if TSH ≥10 mIU/L, and followed an individualized approach in young patients with SCH (<70 years) with TSH ≤10 mIU/L depending upon the presence and absence of symptoms of SCH. These guidelines recommended following the age-specific local reference ranges for serum TSH levels to decide in taking a step to treat subjects with SCH or simply follow-up with monitoring of TSH in both situations. Our meta-analysis showed a significant increased CIMT in subjects with SCH versus EU controls only at TSH values of ≤10.0 mU/l, but showed a near significant increase in CIMT at TSH values of ≤10.0 mIU/L. However, this review emphasizes thyroxin treatment of subjects with SCH at any level of TSH, because such treatment has a significant effect on CIMT reduction both at a prior treatment TSH ≤10.0 mU/l as well as TSH >10.0 mU/l (Fig. 5b). We also observed that subjects with SCH with a prior treatment TSH >10.0 mU/l exhibited a significantly higher WMD decrease in CIMT as compared to SCH with a prior treatment TSH ≤10.0 mU/L (WMD = -0.35 vs. -0.30), but both showed a significant CIMT reduction from pre- to post-treatment. Some studies report against treating SCH because these studies did not find any evidence of SCH association with CVD outcomes at any level of TSH meeting SCH diagnosis. The study by Cappola et al. did not find any association between SCH and incidence and prevalence of atherosclerotic disease, as well as showed no significant positive effect on CVD outcome with thyroxin treatment.

### Table 3: Metabolic Parameters at baseline in Subclinical Hypothyroid (SCH) subjects and Euthyroid (EU) controls and at Pre-and-Post Rx with thyroxin in SCH subjects.

<table>
<thead>
<tr>
<th>Metabolic Parameters at baseline b/w SCH and EU groups</th>
<th>Changes of Metabolic Parameters at pre-and-post thyroxin Rx in SCH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Studies Sample size (SCH/EU)</td>
<td>WMD (95%CI)</td>
</tr>
<tr>
<td>TC</td>
<td>11</td>
</tr>
<tr>
<td>TG</td>
<td>11</td>
</tr>
<tr>
<td>LDL</td>
<td>12</td>
</tr>
<tr>
<td>HDL</td>
<td>12</td>
</tr>
<tr>
<td>SBP</td>
<td>8</td>
</tr>
<tr>
<td>DBP</td>
<td>8</td>
</tr>
</tbody>
</table>

TC = Total cholesterol, TG = Triglycerides, LDL = Low density lipoprotein, HDL = High density lipoprotein, SBP = Systolic Blood Pressure, DBP = Diastolic Blood Pressure.
Our meta-analysis provided a strong evidence of increased subclinical CVD risks as increased CIMT, higher-level atherogenic lipids, and increased SBP and DBP in subjects with SCH. An increase in CIMT was significantly correlated with an increase in the level of atherogenic lipids. The altered lipid levels could be the major mechanism causing early atherosclerotic vascular changes in subjects with SCH. In all subgroup analyses, the association between increased CIMT in subjects with SCH remained significant except in subjects with SCH with a mean TSH ≤10.0 mIU/l, where SCH was no longer associated with an increased CIMT. Furthermore, we found a greater improvement in CIMT values in subjects with SCH with a thyroxin treatment duration of more than 6 months versus less than 6 months (WMD of CIMT reduction = 0.36 vs. -0.28). Many studies vote for a lifelong treatment with thyroxin and a regular monitoring of thyroid function tests for clinical/overt hypothyroidism; however, no robust evidence exists regarding the duration of long-term treatment of otherwise healthy subjects with SCH. Moreover, some studies suggest little or no symptomatic benefit from the treatment of SCH57-59. According to the 2013 SCH treatment guidelines by Pearce et al., there is emphasis on starting the treatment of SCH if a patient has signs and symptoms or other conditions, such as diffuse or nodular goiter, diabetes, dyslipidemia, or TSH >10 mU/l, and if there is an improvement in symptoms, then to consider a lifelong treatment.55) Our meta-analysis also showed a significant risk of an increase in CIMT and dyslipidemia especially at TSH >10.0 mU/l and recommended the start of thyroxin treatment in SCH in otherwise healthy young subjects. A meta-analysis by Goa et al. showed that SCH was associated with only SBP but not DBP, but a meta-analysis by Cai et al. and the present meta-analysis showed that Schiff was significantly associated with higher SBP as well as higher DBP when compared with matched EU controls. Furthermore, this meta-analysis also observed a significant decrease in both SBP (p=0.02) and DBP (p=0.01) with thyroxin treatment. This evidence suggested that subjects with SCH are at a significantly higher risk of subclinical CVD risk factors and can obtain benefits from in time long-term thyroxin treatment.

The strengths of the present meta-analysis are as follows: (1) We defined a strict inclusion and exclusion criteria. (2) We conducted a different subgroup analysis to reduce heterogeneity and publication bias. (3) We also conducted an analysis for CIMT differences in subjects with SCH and EU controls after removing all studies that used subjects with any other conditions, such as smoking, hypertension, and diabetes, obese with non-alcoholic fatty liver disease, with BMI >25 kg/m², subjects with Polycystic Ovary Syndrome (PCOS); the results were still significant. (4) We conducted the dose meta-regression, which showed that an increase in each unit thyroxin dose has an additive effect on CIMT reduction, although the model was not significant due to the limited number of studies included in the model.

The present meta-analysis has the following limitations: (1) Most of the clinical trials discussing the treatment of subjects with SCH were not double-blind, randomized controlled trials; however, such
and, therefore, are more likely to be missed in the search for relevant trials. All these types of biases are more likely to affect studies with smaller participants to a greater degree than large trials.

**Conclusion**

In summary, this meta-analysis suggests that there is a strong association of SCH and increased CIMT, along with dyslipidemia and increased SBP and DBP. Such association has been proven by many other studies. The increased CIMT could be related to the associated increase in TSH level, dyslipidemia, obesity, and hypertension. This meta-analysis also suggests that thyroxin treatment has significant beneficial effects on CIMT reduction, weight, hypertension, and a positive improvement in lipids, especially thyroxin treatment longer than 6 months. Double-blind, randomized controlled clinical trials with a longer duration of follow-up are needed to clearly delineate the risk of SCH with CVD risk factors.

**Conflict of Interests**

M. Aziz, Y. Kandimalla, A. Machavarapu, A. Sexena, S. Das, A. Younus, M. Nguyen, R. Malik, C. MA. Latif, Humayun, IM. Khan, A. Adus, A. Rasool, E. Veledar, K. Nasir state that no conflict of interest exists. No off-label or investigational use of a drug was performed as part of this research.
References

12) Allan PL, Mowbray PJ, Lee AJ and Fowkes FG: Relationship between carotid intima-media thickness and symptomatic and asymptomatic peripheral arterial disease. The Edinburgh Artery Study. Stroke, 1997; 28: 348-353
14) Cikim AS, Oflaz H, Ozsey N, Cikim K, Umman S, Meric M, Sencer E and Molvallari S: Evaluation of endothelial function in subclinical hypothyroidism and subclinical hyperthyroidism. Thyroid, 2004; 14: 605-609
26) Cerbone M, Calpalbo D, Wasniewska M, Alfano S, Mat-


31) RevMan 5 download | Cochrane Community. 2016;


37) RevMan 5 download | Cochrane Community. 2016;


48) Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, Tracy RP and Ladenson PW: Thyroid Status, Cardiovascular Risk, and Mortality in Older Adults: The Cardiovascular Health Study. JAMA, 2006; 295: 1033-1041


53) Khandelwal D and Tandon N: Overt and subclinical hypothyroidism: who to treat and how. DRUGS, 2012;
56) Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, Tracy RP and Ladenson PW: Thyroid status, cardiovascular risk, and mortality in older adults. JAMA, 2006; 295: 1033-1041